New Horizons in Immunology and Immunotherapy of Acute Leukemias and Related Disorders

Lanza, Francesco; Rondoni, Michela; Zannetti, Beatrice Anna

doi:10.3390/cancers15092422

Cancers

2023

DOI: 10.3390/cancers15092422

|View full text |Cite

New Horizons in Immunology and Immunotherapy of Acute Leukemias and Related Disorders

Francesco Lanza

Michela Rondoni

Beatrice Anna Zannetti

Abstract: Accumulating data have shown that molecular aberrations have the potential to trigger the development of acute leukemia, and that the routine application of novel molecular biology technologies has facilitated the development of investigational drugs which target driver genetic mutations [...]

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Novel insights and therapeutic approaches in secondary AML

Marconi,

Rondoni,

Zannetti

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Secondary acute myeloid leukemia (sAML) presents as a complex and multifaceted ensemble of disorders, positioning itself as both a challenge and an intriguing frontier within hematologic oncology. Its origins are diverse, stemming from antecedent hematologic conditions, germline predisposing mutations, or the sequelae of cytotoxic therapies, and its development is driven by intricate genetic and epigenetic modifications. This complexity necessitates a diverse array of therapeutic strategies, each meticulously tailored to address the distinctive challenges sAML introduces. Such strategies require a personalized approach, considering the variegated clinical backgrounds of patients and the inherent intricacies of the disease. Allogeneic stem cell transplantation stands as a cornerstone, offering the potential for curative outcomes. This is complemented by the emergence of innovative treatments such as CPX-351, venetoclax, and glasdegib, which have demonstrated promising results in enhancing prognosis. The evolving landscape of sAML treatment underscores the importance of continued research and innovation in the field, aiming not only to improve patient outcomes but also to deepen our understanding of the disease’s biological underpinnings, thereby illuminating pathways toward more effective and individualized therapies.

show abstract

Novel insights and therapeutic approaches in secondary AML

Marconi,

Rondoni,

Zannetti

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

New Horizons in Immunology and Immunotherapy of Acute Leukemias and Related Disorders

Cited by 1 publication

References 17 publications

Novel insights and therapeutic approaches in secondary AML

Novel insights and therapeutic approaches in secondary AML

Contact Info

Product

Resources

About